💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Indalpine

CHEMBL276520 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
228.3 g/mol
LogP
3.3
Phase
4

This selective serotonin reuptake inhibitor (SSRI) was one of the earliest drugs in its class, developed in France to treat depression by increasing serotonin levels in the brain. It was withdrawn from clinical use due to rare but serious blood cell disorders.

分子量

228.3300 g/mol

LogP

3.30

TPSA

27.80 Ų

リピンスキーの五則

適合

作用機序

Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
c1ccc2c(CCC3CCNCC3)c[nH]c2c1

                

                

                
                

                    
InChI

                    
InChI=1S/C15H20N2/c1-2-4-15-14(3-1)13(11-17-15)6-5-12-7-9-16-10-8-12/h1-4,11-12,16-17H,5-10H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H20N2

                    

                    
                    

                        
HBD / HBA

                        
2 / 1

                    

                    
                    

                        
回転可能結合数

                        
3

                    

                    
                    
                    

                        
重原子数

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
This selective serotonin reuptake inhibitor (SSRI) was one of the earliest drugs in its class, developed in France to treat depression by increasing serotonin levels in the brain. It was withdrawn from clinical use due to rare but serious blood cell disorders.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Indalpine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL276520.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 44668.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.